Discussion  by unknown
The lack of change in prevalence of Bcl-2 and Bax
protein levels neither supports nor refutes the occurrence of
apoptosis in this model. Bcl-family proteins are known to
exert many of their functions in the short term by altering
their subcellular localization or through homodimerization
and heterodimerization, rather than solely by means of de
novo expression.27-29 Unchanged bcl-xL protein abundance,
despite increased mRNA transcript abundance, might be
due to the acute nature of the stimulus.
Conclusion
We have observed increased apoptotic cell death and altered
expression of regulators and effectors of apoptosis in the
hearts of neonatal lambs subjected to a clinically relevant
period of cardioplegic arrest. Refinement of our model and
techniques will allow finer discrimination of the extent of
apoptosis and more specific determination of the instigating
stimuli. Further work will be required to evaluate the short-
and long-term consequences of postcardioplegia myocardial
apoptosis. Eventually, understanding the role of apoptosis in
the neonatal heart’s response to cardioplegia might provide
new insight into the study of myocardial protection tech-
niques and the phenomenon of myocardial stunning.
We acknowledge the expert technical assistance of Oliva Smith
and Kurt Bedell.
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Discussion
Dr Carl L. Backer (Chicago, Ill). I am filling in for Ross
Ungerleider, and right now I wish Ross were here.
Dr Hammel and associates from the University of Iowa Chil-
dren’s Hospital have performed a comprehensive evaluation of the
relationship between myocardial apoptosis, apoptosis-related me-
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diators, and cardiopulmonary bypass with cardioplegic arrest in a
neonatal lamb model. They have demonstrated rather convincingly
on the basis of the 5-fold increase in TUNEL-positive nuclear
myocytes that there is an increase in apoptosis in the fetal myo-
cardium after aortic crossclamping.
This is not something generally on the mind of most congenital
heart surgeons when they are performing an arterial switch proce-
dure, but perhaps it should be. The clinical implications of this
study might be quite significant. As the authors have speculated,
this might contribute to the frequently seen postoperative sag in
cardiac output 6 to 12 hours after neonatal cardiac procedures. We
might also speculate that it could be a cause of later ventricular
dysfunction in certain lesions.
I have several questions for the authors.
Can you speculate on potential clinical methods that would be
used to prevent this apoptosis and perhaps modulate the effect seen
in your model? Specifically, do you believe there is any contribu-
tion of anti-inflammatory–type measures, such as Decadron ad-
ministration, aprotinin, or leukocyte depletion to decrease apopto-
sis?
You raised the question yourself regarding the lack of corrob-
orating evidence with regard to the modest increase of caspase 3.
Do you think the TUNEL positivity might actually be a false-
positive result?
Finally, why did you select 6 hours for your end point? With
my limited understanding, I am not sure that we are sure that this
apoptosis is actually going to become cell death.
I congratulate you on a well-designed, well-executed, and
nicely reported experiment. You have greatly heightened the
awareness and possible implications of apoptosis in neonatal car-
diac surgery.
Dr Hammel. Thank you, Dr Backer, for your kind comments.
To answer your first question regarding potential clinical tech-
niques that could be used to prevent apoptosis and modulate this
effect, current techniques for myocardial protection were devel-
oped, with myocardial stunning and myocardial necrosis protec-
tion as end points. Just the knowledge that apoptosis is a poten-
tially important end point suggests investigation of techniques that
prevent apoptosis. There are ways to inhibit apoptosis, for exam-
ple, through caspase inhibitors, which are being tested in other
models of cardiac apoptosis, or through use of alternative car-
dioplegic agents, such as potassium channel openers, which stabi-
lize the mitochondrial membrane potential during ischemia and
prevent mitochondrially induced apoptosis.
With regard to anti-inflammatory measures to decrease apopto-
sis, we were suspicious that inflammatory mediators, which are
known to be increased during cardiopulmonary bypass, might
potentially be the cause of this activation. We did not find evidence
of that because we would expect to see an activation of caspase 8,
which transmits the signal from those inflammatory mediators at
the cell surface into the downstream mediators. We did not see that
activity, but I would not say that we have ruled that possibility out.
Furthermore, when inflammatory cells are recruited into the
myocardium after reperfusion, those cells increase the oxidative
stress to which the mitochondrion is exposed and favor the induc-
tion of apoptosis. Therefore, there is a potential role for anti-
inflammatory agents, such as steroids or complement inhibitors,
during cardioplegia.
With regard to caspase 3 activity, it is a bit troubling not to see
activation. Of course it is possible that this TUNEL stain is a
false-positive result. But because this is the foundation that we are
going to be basing a lot of work on, we went to some lengths to
confirm it. The DNA laddering is strong corroborative evidence
because DNA laddering is difficult to observe in tissue DNA
extracts. When it is present, it has historically been a sine qua non
of apoptotic DNA degradation. Furthermore, we repeated the
TUNEL assays in a second separate laboratory, using different
reagents from a different manufacturer and using both formalin-
fixed and cryostat sections, and we came to the same conclusions,
although the numbers were slightly different.
The lack of caspase 3 activation has actually been observed in
human models and other large-animal models. It is more the rodent
models and cell culture systems in which large increases in caspase
activity have been reported. Figuring out why caspase 3 activity is
not increased might end up teaching us something about the
sequelae of cardioplegia in this model.
Why the 6-hour time point? Dr Caldarone’s interest in this
subject came from the observation that postoperative myocardial
dysfunction seemed to actually increase as neonates approached
that 6-hour time point. Therefore, we picked a time point at which
apoptosis might be contributing to that phenomenon. We have
looked at other time points, and we see TUNEL positivity in fact
increasing beyond 6 hours, but we do not quite have that data ready
to present.
Dr Bradley S. Allen (Oak Lawn, Ill). I have 3 questions. First,
on your bypass controls, did you cool to the same temperature?
This is important because apoptosis can be caused by temperature
changes.
Second, your first statement was that the neonate is in a
proapoptotic state, and this is the reason for the increased rate of
apoptosis. However, apoptosis has been shown to occur in adult
hearts subjected to cardioplegic arrest. How do you know there is
more apoptosis in the neonate compared with that in the adult? Do
you have a comparison group of mature hearts subjected to the
same ischemic stress to prove this statement?
Last, did you perform any hemodynamic measurements? I
would expect them to be normal after only a 70-minute crossclamp
interval with good myocardial protection. If that is the case, the
importance of this study is that it shows damage is occurring even
with good myocardial protection. In contrast, if the hemodynamics
were poor, then this means the method of protection was inade-
quate, and that poor protection was the cause of the increased rate
of apoptosis.
Dr Hammel. Those are 3 very interesting questions.
The first question was about the temperature. Although for the
bypass-only animals the prime was warmed a bit more before we
went on so that they would not have rhythm disturbances when
they were first started on bypass, they were all passively cooled,
and all the lambs pretty quickly achieved a temperature of about
28°C during the bypass runs. Therefore yes, they were all cooled
to approximately the same temperature.
The issue of the maturity of the subjects is also interesting. In
fact, we have performed this experiment comparing with 6-week-
old lambs who are significantly larger—about 4 times the body
weight—and we see some apoptosis, but we see much less. We
have also seen that as compared with those animals after surgical
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intervention, caspase activity is much higher in these neonates than
it is in those 6-week animals, and we will be presenting that
information at a later date as well.
With regard to hemodynamics, I think that is a very important
next step. We need to find out whether hemodynamic changes
occur in our model system and whether they are causally related to
apoptosis. We are working on it.
Dr Pedro L. del Nido (Boston, Mass). Did you use cat-
echolamines after pumping on any of these animals?
Dr Hammel. No, none of the animals received any inotropic
agents. They all got transfusion and fluids as necessary to support
their pressure.
Dr del Nido. Are they then allowed to regulate their own blood
pressure?
Dr Hammel. Yes, they were all allowed to control their own
pressure. They received some interventions as needed. Some of the
animals were defibrillated, and some were given lidocaine, but not
as a pattern.
Dr del Nido. It is one of the things that at some point you are
going to have to need to control for because endogenous cat-
echolamines, exogenous catecholamines (eg, dopamine), or both,
are widely known to augment apoptosis. Therefore, it is something
for which you will need to control.
My other question is this: Did you take your samples from the
right ventricle or the left ventricle?
Dr Hammel. The samples for histologic studies were all taken
from the middle of the left ventricular free wall. The samples for
the rest of the studies were taken from the remainder of the left
ventricular free wall.
Dr del Nido. Just a word of caution. A lot of the apoptotic
signal, in fact, is driven by mitochondria, and subsarcolemmal
mitochondria are not as involved as the interfibrillar mitochondria.
There is a difference between hypertrophied versus nonhypertro-
phied ventricles, and physiologic hypertrophy, such as that seen in
the left ventricle postnatally, in fact grows a lot of mitochondria
very quickly but does not have a lot in the beginning. The right
ventricle early on, because it is an important ventricle in the
neonate, has a lot more mitochondria, which it loses in the first few
days after birth. Again, you are going to have to look at both
ventricles. It would be very interesting to repeat your exact study
and look at the right ventricle. In fact, you might find that this
phenomenon is even more dramatic in the right ventricle.
Dr Hammel. In fact, earlier in the study we looked at the right
ventricle. I did not have a complete data set regarding that tissue,
and therefore I did not present it. But TUNEL staining and lad-
dering were also positive, and the rate of TUNEL-positive nuclei
was, in fact, just about the same in the right and the left ventricle.
Dr Frank L. Hanley (Stanford, Calif). I am assuming, because
you did not comment on it, that the spatial distribution throughout
the volume of myocardium demonstrated a random distribution of
apoptotic cells.
Dr Hammel. That is correct.
Dr Hanley. If that is correct, why did those particular cells
become apoptotic? Could you speculate on the possibility that
these were already cells that were on their way to cell death, and
you just stimulated them along? Do you have any other explana-
tion for why the individual cells that did become apoptotic in this
setting did so?
Dr Hammel. That is a very interesting and provocative idea.
Why these nuclei? They were evenly distributed as far as we could
see. The other cells are all exposed to the same stimulus, and they
must be affected as well. I think that you are probably right, these
cells probably were cells that were just about to undergo apoptosis
and were pushed over. However, they might be the tip-of-the-
iceberg evidence of a phenomenon in which early and more subtle
changes of apoptosis, such as cytochrome c release and mitochon-
drial dysfunction, might be occurring in a larger population of
cells. That larger population might account for hemodynamic
changes, whereas the 1% of cells that are TUNEL positive is not
a significant loss on its own.
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